EPCAM and neoplasm: To assess the role of EpCAM in cisplatin resistance, untreated patient tumor cells, SCC15 and FaDu cells, were transfected with siEpCAM and si-scramble for 48 h, washed and followed by cisplatin treatment for an additional 48 h and assessed for cell viability (Supplementary Fig. S2).